AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36878237 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks plus chemotherapy (paclitaxel 175 mg/m2)
Number of subjects: 617
Study 36878237 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (paclitaxel 175 mg/m2)
Number of subjects: 617
Study 36878239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 17160
Study 36878264 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1623
Study 36878264 — intervention group
Group type: COMPARATOR
Intervention: Health education program
Number of subjects: 1623
Study 36878302 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopist-facilitated intubation
Number of subjects: 45
Study 36878302 — intervention group
Group type: COMPARATOR
Intervention: Standard intubation
Number of subjects: 45
Study 36878311 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism (SubHypo)
Number of subjects: 253
Study 36878311 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid
Number of subjects: 253
Study 36878326 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE4/CCR5 knockout heterozygotes
Number of subjects: 2
Study 36878326 — intervention group
Group type: COMPARATOR
Intervention: APOE4/wild-type heterozygotes
Number of subjects: 2
Study 36878389 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized care (smoking cessation and SDM delivered remotely by trained counselors)
Number of subjects: 0
Study 36878389 — intervention group
Group type: COMPARATOR
Intervention: Usual care (providers delivering smoking cessation and SDM on site)
Number of subjects: 0
Study 36878649 — intervention group
Group type: EXPERIMENTAL
Intervention: QC-POD intervention (periopeartive intervention at least two times per day, delirium screening, non-pharmacological preventive measures)
Number of subjects: 0
Study 36878649 — intervention group
Group type: COMPARATOR
Intervention: Baseline control period (no specific intervention mentioned)
Number of subjects: 0
Study 36878658 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe at Home programme
Number of subjects: 202
Study 36878658 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted group
Number of subjects: 202
Study 36878666 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and education (12-week supervised)
Number of subjects: 63
Study 36878666 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 63
Study 36878666 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and education
Number of subjects: 63
Study 36878672 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic CAD-score device with a cut-off ≤20 for obstructive CAD rule-out
Number of subjects: 1683
Study 36878672 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic CAD-score device with a cut-off ≤20 applied in ESC-PTP 5% to <15% patients
Number of subjects: 1683
Study 36878701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK)
Number of subjects: 71
Study 36878701 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 71
Study 36878701 — intervention group
Group type: COMPARATOR
Intervention: Tenecteplase (TNK) and Alteplase
Number of subjects: 71
Study 36878715 — intervention group
Group type: EXPERIMENTAL
Intervention: Airdoc retinal artificial intelligence system (ARAS) for detecting multiple fundus diseases
Number of subjects: 4795
Study 36878715 — intervention group
Group type: EXPERIMENTAL
Intervention: Airdoc retinal artificial intelligence system (ARAS)
Number of subjects: 4795
Study 36878722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-early neurologic improvement (U-RNI) defined as improvement by 2 or more points on the Los Angeles Motor Scale (LAMS) score between prehospital and early post-ED arrival examinations.
Number of subjects: 1245
Study 36878722 — intervention group
Group type: EXPERIMENTAL
Intervention: U-RNI
Number of subjects: 1245
Study 36878897 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermostable ID93 + GLA-SE vaccine
Number of subjects: 0
Study 36878897 — intervention group
Group type: COMPARATOR
Intervention: Non-thermostable two-vial vaccine presentation
Number of subjects: 0
Study 36879012 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-EGFR-ILs-dox 50 mg/m²
Number of subjects: 48
Study 36879078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Eating Disorders (CBT-E)
Number of subjects: 63
Study 36879087 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg BID
Number of subjects: 415
Study 36879087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 36879107 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients
Number of subjects: 282
Study 36879107 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM patients
Number of subjects: 282
Study 36879107 — intervention group
Group type: COMPARATOR
Intervention: Rituximab therapy in T1DM patients
Number of subjects: 282
Study 36879107 — intervention group
Group type: COMPARATOR
Intervention: Healthy control individuals
Number of subjects: 282
Study 36879129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous evinacumab 15 mg/kg
Number of subjects: 51
Study 36879129 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study 36879199 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCS-ADL-MCI scale at baseline
Number of subjects: 769
Study 36879199 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCS-ADL-MCI scale at 36 months
Number of subjects: 769
Study 36879199 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 769
Study 36879199 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent/discriminant validity
Number of subjects: 769
Study 36879199 — intervention group
Group type: EXPERIMENTAL
Intervention: Known-groups validity
Number of subjects: 769
Study 36879199 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsiveness
Number of subjects: 769
Study 36879259 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted intervention for resolving unaddressed legal issues
Number of subjects: 800
Study 36879259 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 800
Study 36879265 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (low muscle mass and strength)
Number of subjects: 171
Study 36879284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab monotherapy
Number of subjects: 0
Study 36879292 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie food images versus baseline (H vs. X)
Number of subjects: 20
Study 36879292 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie food images versus baseline (L vs. X)
Number of subjects: 20
Study 36879292 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie food images versus low-calorie food images (H vs. L)
Number of subjects: 20
Study 36879301 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based therapy (MBT)
Number of subjects: 175
Study 36879301 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 175
Study 36879297 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fermented by Lacticaseibacillus rhamnosus CNCM I-3690
Number of subjects: 16
Study 36879297 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fermented by Streptococcus thermophilus CNCM I-1630 and Lactobacillus delbrueckii subsp. bulgaricus CNCM I-1519
Number of subjects: 16
Study 36879297 — intervention group
Group type: COMPARATOR
Intervention: Chemically acidified milk (placebo)
Number of subjects: 16
Study 36879314 — intervention group
Group type: EXPERIMENTAL
Intervention: SexHealth Mobile intervention (same-day, onsite clinical consultation and contraception)
Number of subjects: 98
Study 36879314 — intervention group
Group type: EXPERIMENTAL
Intervention: SexHealth Mobile intervention
Number of subjects: 98
Study 36879314 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 98
Study 36879333 — intervention group
Group type: EXPERIMENTAL
Intervention: Active phase of the augmented platform (orientation cueing during location recording)
Number of subjects: 0
Study 36879333 — intervention group
Group type: COMPARATOR
Intervention: Passive phase of the augmented platform (only recording location)
Number of subjects: 0
Study 36879386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) use
Number of subjects: 18
Study 36879386 — intervention group
Group type: COMPARATOR
Intervention: Better hearing ear alone
Number of subjects: 18
Study 36879386 — intervention group
Group type: COMPARATOR
Intervention: Children with normal hearing (NH)
Number of subjects: 18
Study 36879424 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab with statin therapy (after achieving very low LDL-C levels)
Number of subjects: 18924
Study 36879424 — intervention group
Group type: COMPARATOR
Intervention: Placebo with statin therapy
Number of subjects: 18924
Study 36879584 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced platelet-rich fibrin (A-PRF)
Number of subjects: 15
Study 36879584 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 15
Study 36879786 — intervention group
Group type: EXPERIMENTAL
Intervention: KL-A167 900mg intravenously once every 2 weeks until confirmed disease progression, intolerable toxicity, or withdrawal of informed consent
Number of subjects: 153
Study 36880049 — intervention group
Group type: EXPERIMENTAL
Intervention: IHAT (iron hydroxide adipate tartrate)
Number of subjects: 642
Study 36880049 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate (FeSO4)
Number of subjects: 642
Study 36880127 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteocalcin
Number of subjects: 848
Study 36880127 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoprotegerin
Number of subjects: 848
Study 36880127 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopontin
Number of subjects: 848
Study 36880127 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 848
Study 36880261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stress response using an arithmetic task in patients with HT&DM
Number of subjects: 62
Study 36880261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stress response using an arithmetic task in patients with HT
Number of subjects: 62
Study 36880426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab rechallenge
Number of subjects: 46
Study 36880426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab rechallenge in CRICKET trial
Number of subjects: 46
Study 36880426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab rechallenge in CAVE trial
Number of subjects: 46
Study 36880866 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop (HCL) insulin delivery with faster insulin aspart (Fiasp)
Number of subjects: 25
Study 36880866 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin aspart (IAsp)
Number of subjects: 25
Study 36880910 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS + NRT
Number of subjects: 35
Study 36880910 — intervention group
Group type: COMPARATOR
Intervention: SMS + NRT + coaching
Number of subjects: 35
Study 36880917 — intervention group
Group type: EXPERIMENTAL
Intervention: Online predeparture intervention focused on risk and protective factors
Number of subjects: 650
Study 36880945 — intervention group
Group type: EXPERIMENTAL
Intervention: MR fingerprinting sequence with water and fat separation for ECV quantification
Number of subjects: 0
Study 36880945 — intervention group
Group type: COMPARATOR
Intervention: Fat fraction (FF) quantification
Number of subjects: 0
Study 36880945 — intervention group
Group type: COMPARATOR
Intervention: Water relaxation time quantification
Number of subjects: 0
Study 36880949 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA) for PTMC with US-detected capsular invasion
Number of subjects: 461
Study 36880949 — intervention group
Group type: COMPARATOR
Intervention: Microwave ablation (MWA) for PTMC without US-detected capsular invasion
Number of subjects: 461
Study 36880949 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 461
Study 36881032 — intervention group
Group type: EXPERIMENTAL
Intervention: Olamkicept 600 mg
Number of subjects: 91
Study 36881032 — intervention group
Group type: EXPERIMENTAL
Intervention: Olamkicept 300 mg
Number of subjects: 91
Study 36881032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 36881034 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (2 g)
Number of subjects: 11983
Study 36881034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11983
Study 36881247 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLD patients
Number of subjects: 249
Study 36881247 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 249
Study 36881285 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 141
Study 36881285 — intervention group
Group type: EXPERIMENTAL
Intervention: cDMARDs
Number of subjects: 141
Study 36881285 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs
Number of subjects: 141
Study 36881285 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of myalgia
Number of subjects: 141
Study 36881394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 739
Study 36881394 — intervention group
Group type: COMPARATOR
Intervention: Not frail
Number of subjects: 739
Study 36881394 — intervention group
Group type: COMPARATOR
Intervention: Prefrail
Number of subjects: 739
Study 36881394 — intervention group
Group type: COMPARATOR
Intervention: Frail
Number of subjects: 739
Study 36881394 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty status at baseline
Number of subjects: 739
Study 36881394 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty change
Number of subjects: 739
Study 36881421 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR
Number of subjects: 1732
Study 36881421 — intervention group
Group type: EXPERIMENTAL
Intervention: RbPET
Number of subjects: 1732
Study 36881446 — intervention group
Group type: EXPERIMENTAL
Intervention: VACT-CP (Veteran ACT for Chronic Pain)
Number of subjects: 20
Study 36881446 — intervention group
Group type: COMPARATOR
Intervention: Waitlist and treatment-as-usual control
Number of subjects: 20
Study 36881458 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to controller medication (inhaled corticosteroids)
Number of subjects: 200
Study 36881458 — intervention group
Group type: COMPARATOR
Intervention: Unmet social needs
Number of subjects: 200
Study 36881458 — intervention group
Group type: COMPARATOR
Intervention: Scarcity and future discounting
Number of subjects: 200
Study 36881542 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative treatment for anemia and/or iron deficiency
Number of subjects: 1494
Study 36881542 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment for anemia and/or iron deficiency
Number of subjects: 1494
Study 36881542 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of iron deficiency at D-1/D0
Number of subjects: 1494
Study 36881542 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of iron deficiency at D30
Number of subjects: 1494
Study 36881542 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of patients with anemia and/or iron deficiency at D-1/D0
Number of subjects: 1494
Study 36881542 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of patients with anemia and/or iron deficiency at D30
Number of subjects: 1494
Study 36881542 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of patients with both anemia and iron deficiency at D-1/D0
Number of subjects: 1494
Study 36881542 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of patients with both anemia and iron deficiency at D30
Number of subjects: 1494
Study 36881575 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated 360-degree goniophotography using the NIDEK Gonioscope GS-1
Number of subjects: 20
Study 36881769 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36881780 — intervention group
Group type: EXPERIMENTAL
Intervention: IN-alert HF state (multi-sensor HeartLogic Index >16)
Number of subjects: 411
Study 36881780 — intervention group
Group type: EXPERIMENTAL
Intervention: RDI ≥ 30 episodes/h (severe sleep apnea)
Number of subjects: 411
Study 36881780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IN-alert HF state and RDI ≥ 30 episodes/h
Number of subjects: 411
Study 36881782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelabresib and ruxolitinib
Number of subjects: 84
Study 36881820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 200 mg
Number of subjects: 0
Study 36881820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 0
Study 36881820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36881899 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36881901 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental sleep disturbances (ESDs)
Number of subjects: 24
Study 36881901 — intervention group
Group type: COMPARATOR
Intervention: Sleep control protocol (8-hour sleep opportunity)
Number of subjects: 24
Study 36881945 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight group (OG, n=44, 59% female, mean age 51.68 years, EDSS: 4.71)
Number of subjects: 106
Study 36881945 — intervention group
Group type: COMPARATOR
Intervention: Lean group (LG, n=62, 71% female, mean age 48.37 years, EDSS: 4.60)
Number of subjects: 106
Study 36882015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Immunotherapy (SLIT)
Number of subjects: 0
Study 36882015 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro study with Artemisia annua
Number of subjects: 0
Study 36882136 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1414
Study 36882136 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1414
Study 36882181 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 36
Study 36882181 — intervention group
Group type: COMPARATOR
Intervention: Placebo tDCS
Number of subjects: 36
Study 36882246 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation programme (3-6 weeks)
Number of subjects: 154
Study 36882246 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 154
Study 36882302 — intervention group
Group type: EXPERIMENTAL
Intervention: Government-regulated rehabilitation guideline
Number of subjects: 303
Study 36882409 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, carfilzomib, and dexamethasone
Number of subjects: 0
Study 36882434 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI in the range 25.0-29.9 kg/m²
Number of subjects: 18209
Study 36882434 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline waist circumference
Number of subjects: 18209
Study 36882456 — intervention group
Group type: EXPERIMENTAL
Intervention: H3-WT tumours with ACVR1 or EGFR mutations
Number of subjects: 5
Study 36882456 — intervention group
Group type: EXPERIMENTAL
Intervention: H3-WT tumours
Number of subjects: 5
Study 36882474 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous Beta-hydroxybutyrate (BHB)
Number of subjects: 41
Study 36882474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 36882483 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured postoperative rehabilitation
Number of subjects: 288
Study 36882483 — intervention group
Group type: COMPARATOR
Intervention: Standard approach after surgery
Number of subjects: 288
Study 36882562 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral minocycline 100 mg twice daily for 12 months
Number of subjects: 5
Study 36882705 — intervention group
Group type: EXPERIMENTAL
Intervention: GAITRite® Platinum Plus Classic (26')
Number of subjects: 95
Study 36882705 — intervention group
Group type: COMPARATOR
Intervention: GAITRite® CIRFACE (VI)
Number of subjects: 95
Study 36882759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG); cycling exercise program, 8 sessions within 3 months.
Number of subjects: 127
Study 36882759 — intervention group
Group type: COMPARATOR
Intervention: Active control group (aCG); health recommendations.
Number of subjects: 127
Study 36882775 — intervention group
Group type: EXPERIMENTAL
Intervention: Socazolimab + nab-paclitaxel + cisplatin (TP)
Number of subjects: 64
Study 36882775 — intervention group
Group type: COMPARATOR
Intervention: Placebo + nab-paclitaxel + cisplatin (TP)
Number of subjects: 64
Study 36882804 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 90
Study 36882804 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 90
Study 36882942 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg once daily
Number of subjects: 66
Study 36882942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 36882942 — intervention group
Group type: COMPARATOR
Intervention: Apremilast 30 mg twice daily
Number of subjects: 66
Study 36882942 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Number of subjects: 66
Study 36882942 — intervention group
Group type: COMPARATOR
Intervention: Apremilast
Number of subjects: 66
Study 36883141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CCR2/5 antagonist)
Number of subjects: 392
Study 36883141 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant (bradykinin antagonist)
Number of subjects: 392
Study 36883141 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast (PDE4 inhibitor)
Number of subjects: 392
Study 36883141 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib/Famotidine (COX2/histamine blockade)
Number of subjects: 392
Study 36883141 — intervention group
Group type: EXPERIMENTAL
Intervention: IC14 (anti-CD14)
Number of subjects: 392
Study 36883141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa (inhaled DNase)
Number of subjects: 392
Study 36883141 — intervention group
Group type: EXPERIMENTAL
Intervention: Razuprotafib (Tie2 agonist)
Number of subjects: 392
Study 36883141 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone and remdesivir
Number of subjects: 392